Brainsway AI Stock Analysis
Want to see IL:BWAY full AI Analyst Report?
Brainsway (BWAY) AI Stock Analysis
Brainsway
(TASE:BWAY)
Brainsway's overall score of 71 is driven by its exceptional financial turnaround and a highly positive earnings call, which confirm strong commercial execution and a bright growth outlook. The company's robust, debt-free balance sheet and excellent cash flow generation provide a solid foundation. However, the score is significantly weighed down by weak technicals, with the stock in a clear downtrend across all major moving averages, and a high P/E ratio that leaves little room for error. The bearish market sentiment reflected in the technical indicators is the primary risk offsetting the company's strong fundamental performance.
Brainsway (BWAY) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 1.22B
- Dividend Yield
- ―
- Average Volume (3M)
- 83.44K
- Price to Earnings (P/E)
- 35.7
- Beta (1Y)
- 0.65
- Revenue Growth
- 15.22%
- EPS Growth
- 33.08%
- Country
- Israel
- Employees
- 129
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
Brainsway Business Overview & Revenue Model
Company Description
Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's...
How the Company Makes Money
BrainsWay primarily makes money by selling and/or leasing its Deep TMS systems to healthcare providers (such as psychiatry and neurology clinics) and generating ongoing revenue tied to the installed base of systems. Key revenue streams typically incl...
Brainsway Earnings Call Summary
The call was strongly positive, marked by 34% revenue growth, 44% growth in system shipments, expanding gross and operating margins, higher cash flow, increased reimbursement coverage, strong demand for SWIFT and OCD, and an outlook at the upper end of or potentially modestly above prior guidance. The company also reported preliminary clinical results, pending regulatory work, early-stage home-use commercialization and higher operating expenses, but these issues did not outweigh the reported financial and commercial progress.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, management expects results to be at the upper end of its previously issued guidance range, with the potential to modestly exceed those ranges; operating income is expected to be in the upper end of guidance. For 2027, management said there is no formal guidance, but expects operating expenses to increase between 15% to 20%, to continue and increase the margin, and cited book-to-bill of around 1.3 -- 1.4x. Management also expects international revenue growth of between 50% or even 100%, expects partnerships to open up between 50, sometimes even more locations in the next 3 years, and said the Alzheimer's feasibility study is expected to be completed by end of 2027, with a potential multicenter clinical trial costing between $3 million to $4 million over 2.5 or 3 years.
Brainsway Financial Statement Overview
Summary
Brainsway's financials depict a powerful turnaround. Revenue growth is accelerating (38% in 2025), profitability has swung from deep losses to a 14.6% net margin, and cash flow conversion is excellent at 96%. The balance sheet is a fortress with minimal debt (0.08 debt-to-equity) and rapidly growing equity. The only minor concern is slight TTM EBIT margin compression.
Income Statement
78PositiveBalance Sheet
85Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.81M | 56.53M | 41.02M | 31.79M | 27.18M | 29.66M |
| Gross Profit | 53.08M | 42.63M | 30.58M | 23.48M | 20.05M | 23.06M |
| EBITDA | 7.74M | 6.22M | 5.36M | -2.56M | -11.45M | -4.67M |
| Net Income | 10.17M | 8.26M | 2.92M | -4.20M | -13.35M | -6.46M |
Balance Sheet | ||||||
| Total Assets | 127.17M | 112.94M | 94.32M | 62.97M | 64.48M | 75.73M |
| Cash, Cash Equivalents and Short-Term Investments | 64.07M | 69.13M | 69.34M | 45.98M | 47.85M | 57.35M |
| Total Debt | 6.95M | 6.82M | 5.62M | 471.00K | 488.00K | 754.00K |
| Total Liabilities | 40.56M | 34.67M | 32.00M | 21.39M | 19.08M | 18.41M |
| Stockholders Equity | 83.07M | 73.24M | 62.31M | 41.58M | 45.40M | 57.32M |
Cash Flow | ||||||
| Free Cash Flow | 11.60M | 16.27M | 6.50M | -1.10M | -7.82M | -1.35M |
| Operating Cash Flow | 12.06M | 18.02M | 10.30M | 1.28M | -9.76M | 884.00K |
| Investing Cash Flow | -50.81M | -17.49M | 30.31M | -37.41M | 42.17M | -42.22M |
| Financing Cash Flow | -3.09M | -2.21M | 18.26M | -1.03M | -1.55M | 41.52M |
Brainsway Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BWAY, the sentiment is Negative. The current price of 2969.00 is below the 20-day moving average (MA) of 3446.35, below the 50-day MA of 3735.22, and below the 200-day MA of 4191.72, indicating a bearish trend. The MACD of -177.17 indicates Positive momentum. The RSI at 28.00 is Positive, neither overbought nor oversold. The STOCH value of 8.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BWAY.
Brainsway Peers Comparison
Overall Rating
IL:SOFW72Outperform
IL:BWAY71Outperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:BWAY | Brainsway | 2969.00 | 546.00 | 22.53% | |
| IL:ILX | ILEX Medical Ltd. | 4717.00 | -1878.73 | -28.48% | |
| IL:ALMD | Allmed Solutions Ltd. | 29.40 | -1.10 | -3.61% | |
| IL:EPIT | EPITOMEE MEDICAL LTD | 246.60 | -493.90 | -66.70% | |
| IL:SOFW | Sofwave Medical Ltd. | 3683.00 | 783.00 | 27.00% | |
| IL:PLSM | Pulsenmore | 464.20 | -1925.86 | -80.58% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
